Science AI Journal
Medicine · Research topic

Open research questions in Helicobacter pylori-related gastroenterology studies

46 unresolved questions extracted from the limitations and future-work sections of 497 Helicobacter pylori-related gastroenterology studies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • pylori strain typing was not performed; therefore, the association between high-risk viru- lence factors (such as CagA+ and VacA+ strains) and the severity of GML could not be assessed. Furthermore, community-based intervention trials targeting the identified risk factors are warranted to evaluate the cost-effective- ness of public health measures, such as expanding access to potable water and promoting individual dining practices.

    Correlation analysis of Helicobacter pylori infection and pathological changes of gastric mucosa in the population of Jiuquan area, China, and Logistic regression analysis of lesion risk factors · 2026 · DOI

  • Bismuth has been shown to synergise with MET in vitro, but the concentration dependence of this interaction and its clinically relevant dose threshold remain poorly defined, leaving MET dosing in BQT largely empirical.

    A pharmacometric grey zone reconciles high metronidazole resistance rates with bismuth quadruple therapy efficacy in Helicobacter pylori · 2026 · DOI

  • Finally, gastroretentive MET formulations warrant further investigation as a means to further increase intragastric exposure, expand coverage of the grey zone, and reduce systemic toxicity.

    A pharmacometric grey zone reconciles high metronidazole resistance rates with bismuth quadruple therapy efficacy in Helicobacter pylori · 2026 · DOI

  • pylori strain diversity and virulence-genotype distributions differ by region; host CYP2C19 metabolizer frequencies vary by ancestry and affect PPI-based regimens (19); diet and the gastric and gut micro- biota differ (6); and resistance ecology, including primary, dual, and heteroresistance, varies widely between and within countries (11, 16–18).

    Mechanism-matched Helicobacter pylori treatment in the potassium-competitive acid blocker era · 2026 · DOI

  • This study has several limitations that should be considered when interpreting the findings. First, the relatively small sample size, particularly the limited number of H. pylori-positive cases, may have reduced the statistical power to detect significant associations. Second, the uneven distribution of participants across certain blood groups and genotype categories may have influenced the robustness of comparative analyses. Additionally, the cross-sectional design of the study limits the ability to establish causal relationships between H. pylori infection and the variables studied.

    Prevalence of Helicobacter pylori Infection and Its Relationship with ABO Blood Group and Haemoglobin Genotype among Pregnant Women in Onitsha, Nigeria · 2026 · DOI

  • 1 2 3 4-1 4-2 5 6-1 6-2 7 8 H. pylori eradication therapy is suggested for the prevention of gastric cancer in patients with H. pylori gastritis. H. pylori eradication therapy is suggested for patients with confirmed H. pylori infection and gastric hyperplastic polyps ≤10 mm, to achieve polyp regression or size reduction. PCR or sequencing-based testing is suggested for H. pylori infection diagnosis and antibiotic resistance detection to guide first-line treatment selection. Tailored therapy based on clarithromycin resistance testing (antibiotic susceptibility testing) is recommended as first-line eradication therapy for H. pylori infection. Based on clarithromycin resistance testing, 10-day BQT is recommended for resistant strains, and 7-day clarithromycin-based triple therapy for susceptible strains. Ten-day concomitant therapy is recommended as first-line empirical eradication therapy for H. pylori infection. Ten to 14-day BQT may be used as first-line empirical eradication therapy for H. pylori infection. BQT is associated with higher adverse event rates and potential utility as salvage therapy; its use as first-line therapy is suggested when other eradication regimens cannot be used. Clarithromycin-based triple therapy may be used in a limited fashion when antibiotic susceptibility testing is unavailable and regional clarithromycin resistance is expected to be below 15%. P-CAB-based antibiotic combination therapy may substitute for PPI-based antibiotic combination therapy as first-line eradication treatment for H. pylori infection. 9-1 Ten to 14-day BQT is recommended as second-line eradication therapy when clarithromycin-based triple therapy or concomitant therapy has failed. 9-2 When BQT has failed as first-line or second-line therapy, rifabutin-based triple therapy or modified BQT incorporating previously unused antibiotics may be considered. Levofloxacin-based therapy may be attempted in a limited fashion, considering regional resistance patterns. 9-3 Referral to a specialized H. pylori center capable of antibiotic susceptibility testing-guided tailored therapy is suggested when two or more lines of eradication therapy have failed.

    Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition · 2026 · DOI

  • However, this guideline has several limitations. First, the recommendations are based on Korean antibiotic resistance patterns and healthcare infrastructure, limiting direct applicability to other settings, although referring to East Asian countries with similar resistance profiles is feasible. Second, the evidence levels for some recommendations were low or moderate, particularly for salvage therapy, for which Korean RCT evidence is limited. Third, a temporal gap between published guidelines and actual resistance rates is inevitable in rapidly changing environments. Fourth, although multiple cost-effectiveness analyses support tailored therapy,73,76,78,161 comprehensive economic evaluations of all recommended regimens were not conducted. Fifth, accessibility of PCR testing varies across healthcare institutions, particularly in primary care settings.174 Sixth, the recommendations are most directly applicable in settings with comparable molecular diagnostic infrastructure. In environments where DPO-PCR is unavailable, BQT (or mBQT) can serve as a robust empirical backbone, culture-based AST may substitute where feasible, and structured clinical interviews can partially substitute for prescription-history databases such as the Korean DUR system, although specific regimens and durations may require adaptation to local resistance epidemiology.175 Finally, this revision focused on evidence-based updates to the nine KQs and did not formulate separate recommendations for established clinical principles that remained unchanged from the previous guidelines.7-10 These include general H. pylori diagnostic methods (UBT, stool antigen test, RUT, KJHUGR histology, and serology) and their interpretation; timing of diagnostic testing after discontinuation of PPIs or antibiotics; the requirement for post-eradication confirmation testing at least four weeks after treatment completion using a UBT or stool antigen test; established eradication indications such as peptic ulcer disease, post-endoscopic resection of early gastric cancer, and MALT lymphoma; and management of patients with penicillin allergy, for whom amoxicillin-free regimens such as BQT or clarithromycin-metronidazole-based therapy should be prioritized after careful allergy history verification.

    Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition · 2026 · DOI

  • pylori eradication therapy were available; therefore, we could not determine whether TyG or TyG/HDL-C changed after bacterial clearance.

    Association of TyG and TyG/HDL with Helicobacter pylori infection status and urea breath test load: a cross-sectional study · 2026 · DOI

  • Several limitations should be acknowledged. First, the study design limits the mechanistic interpretability of certain compari- sons. Aside from the direct comparison between Groups A and D, other cohorts involved multiple simultaneous changes in variables (e.g., dosing frequency and antibiotic combinations), which pre- clude the isolation of the individual contributions of furazolidone or bismuth. Future research should utilize factorial design trials or head-to-head comparisons of single-variable changes (e.g., vono- prazan b.i.d. dual therapy vs. vonoprazan b.i.d. quadruple therapy) to precisely quantify the additive value of bismuth or secondary antibiotics in high-resistance regions. Second, the retrospective design introduces potential selection and recall biases, which may affect the precision of our reporting. Future large-scale prospective RCTs are needed in the Guizhou region to validate these real-world findings and provide higher-level evidence for regional guideline development. Third, the absence of patient-level AST precludes a definitive causal link between treatment failures and regional resistance. While the “Guizhou Gap” (sub-90% eradication) may be driven by elevated amoxicillin resistance, this remains speculative without phenotypic or genotypic data. Future efforts in Guizhou should prioritize SGT via culture-based AST or molecular screening as the most rational path to achieving optimal eradication thresholds in this multi-ethnic popu- lation. Finally, while our study confirms the efficacy of 14-day regi- mens, it was not designed to determine the minimum effective dosing frequency (e.g., 7-day vs. 14-day) or the impact of varying vonoprazan doses. Future head-to-head trials focusing on dose optimization in high-resistance regions are warranted. standards; even under per-protocol analysis, no regimen achieved the 90% optimal eradication threshold. This indicates that the unique antibiotic resistance profile and socio-demographic factors in Guizhou render a “one-size-fits-all” global approach insufficient. Most notably, this study establishes that once-daily (q.d.) vono- prazan dosing is clinically inadequate for this region, failing to meet the 85% acceptability threshold. While optimizing dosing frequency to twice-daily (b.i.d.) is a necessary, immediate step for empiric treat- ment, the persistent sub-90% success rate suggests that future clinical strategies must prioritize transitioning to SGT. Implementing pre- treatment culture-based AST or molecular resistance screening is the most rational path to overcoming regional resistance barriers. Until such infrastructure is widely accessible, high-dose vonoprazan dual therapy remains the preferred empiric benchmark for refining H. pylori protocols in high-resistance, multi-ethnic frontier regions.

    Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy for Helicobacter pylori eradication in a high-resistance, multi-ethnic region: a multicenter study in Guizhou, China · 2026 · DOI

  • Sequential therapy demonstrated the highest adverse event incidence and the number of antibiotics explained approximately 22% of safety heterogeneity, yet the mechanisms underlying cumulative side effects from multi-drug exposure remain incompletely characterized. Prospective pharmacokinetic and microbiota profiling studies are needed to determine how successive antibiotic phases in sequential therapy interact to increase gastrointestinal irritation, dysbiosis severity, and intolerable reactions compared to simultaneous triple or quadruple H. pylori regimens.

    Efficacy and safety of antibiotic regimens for Helicobacter pylori eradication: a systematic review and meta-analysis · 2026 · DOI

  • The subgroup analysis results for sequential therapy, quadruple therapy, selected dual therapies, and PCAB-based regimens were not adjusted for multiple comparisons and could not fully control for confounding factors such as patient adherence, follow-up completeness, and baseline resistance status. Future research must employ adjusted multiple comparison methods and propensity score matching to isolate the causal effects of specific H. pylori eradication regimen structures on both efficacy and adverse event outcomes.

    Efficacy and safety of antibiotic regimens for Helicobacter pylori eradication: a systematic review and meta-analysis · 2026 · DOI

  • The majority of included studies originated from East Asia, where clarithromycin resistance reached 30% and metronidazole resistance reached 61% as of 2022. Future efficacy analyses must systematically stratify H. pylori eradication regimen performance by regional antimicrobial resistance profiles across Europe, North America, Africa, and Latin America to determine whether superior performance of sequential therapy, quadruple therapy, and PCAB-based regimens holds across diverse resistance backgrounds.

    Efficacy and safety of antibiotic regimens for Helicobacter pylori eradication: a systematic review and meta-analysis · 2026 · DOI

  • Adverse event definitions and severity grading protocols varied substantially across included studies, with some failing to report severity classification entirely. Standardized adverse event reporting protocols for H. pylori antibiotic regimens must be established and validated, including consistent grading of gastrointestinal irritation, microbiota disruption, and drug-drug interaction severity, to enable accurate comparison of tolerability across sequential therapy, quadruple therapy, and PCAB-based regimens.

    Efficacy and safety of antibiotic regimens for Helicobacter pylori eradication: a systematic review and meta-analysis · 2026 · DOI

  • The meta-analysis identified publication year, continental distribution, study design, and acid suppressant type as primary factors contributing to heterogeneity in H. pylori eradication rates, yet these factors explained only a portion of the extremely high heterogeneity (I² > 85%). Future research must systematically investigate unexplained sources of heterogeneity by conducting prospective studies that standardize antibiotic combinations, dosage intensity, treatment duration, and acid suppressant type to isolate the independent effects of regimen structure on eradication efficacy.

    Efficacy and safety of antibiotic regimens for Helicobacter pylori eradication: a systematic review and meta-analysis · 2026 · DOI

  • The closed and fixed-version computational environment substantially limited the scope of hyperparameter tuning, which may have constrained achievable discrimination, calibration performance, and overall model stability; broader hyperparameter optimization may yield improved performance in settings with more flexible computational infrastructure.

    SHAP-explained machine-learning model for high-risk gastric cancer identification · 2026 · DOI

  • The relatively short follow-up period restricts inferences about short-term (2-year) GC risk; longer follow-up and prospective evaluations are needed to assess calibration drift, clinical impact, and whether intensified surveillance for AG/IM reduces GC incidence and mortality.

    SHAP-explained machine-learning model for high-risk gastric cancer identification · 2026 · DOI

  • Future research should examine transmission dynamics, treatment adherence, and rein- fection rates among the adolescent and young adult population in Uganda.

    Prevalence and pre-disposing factors of Helicobacter pylori among patients with gastro-intestinal symptoms attending Mulago Hospital, Kampala, Uganda · 2026 · DOI

  • The analysis also did not account for possible concomitant use of proton pump inhibitors, which would both increase the chances of false negative rapid urease tests as well as alter or “mask” symptoms and their severity.

    Investigating the Prevalence of Upper Gastrointestinal Symptoms and Related Factors Using the Gastroparesis Cardinal Symptom Index in an Endoscopy Cohort in Latvia · 2026 · DOI

  • Whole-genome sequencing has revolutionized microbial genomics by allowing high-resolution analyses to obtain insights into the evolution of pathogenic organisms; however, few studies have specifically focused on strains from Korea, where H.

    Genomic characterization of clinical Helicobacter pylori strains from Korea: insights into phylogeny, pan-genome structure, and virulence factors · 2026 · DOI

  • The dataset captured alcohol frequency but not per-occasion quantity or ethanol grams, precluding dose–response analyses and potentially attenuating alcohol-related effects.

    SHAP-explained machine-learning model for high-risk gastric cancer identification · 2026 · DOI

  • The exclusion of individuals who died within two years after screening to minimize outcome misclassification may have introduced selection or survivorship bias and informative censoring, potentially attenuating estimated risks.

    SHAP-explained machine-learning model for high-risk gastric cancer identification · 2026 · DOI

  • Although there are several factors known to cause gastric ulcers, the mechanism of mucosal injury in the stomach related to gastric ulcers has not been fully clarified.

    Etiopathogenesis of Peptic Ulcers and Prostaglandin Relationship · 2020 · DOI

  • AIM: There is insufficient knowledge on the * duodenal histology and Helicobacter pylori infection in malnourished Bangladeshi children.

    Asymptomatic Duodenitis and <i>Helicobacter pylori</i> associated Dyspepsia in 2-Year-Old Chronic Malnourished Bangladeshi Slum-Dwelling Children: A Cross-Sectional Study · 2020 · DOI

  • BACKGROUND: There are insufficient data in the literature on the presence of Helicobacter pylori in tonsil and adenoid tissue of patients with only airway obstruction.

    Relationship between Helicobacter pylori Adenotonsillar Colonization and Frequency of Adenotonsillitis in Children · 2013 · DOI

  • BACKGROUND: Studies that report prevention of ulcer recurrence among long-term users of nonsteroidal anti-inflammatory drugs (NSAIDs) that do not stratify for Helicobacter pylori status may not be generalizable to the large population of individuals without H pylori.

    Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs · 2002 · DOI

Most-cited papers in Helicobacter pylori-related gastroenterology studies

Most recent work

Find a gap in your own Helicobacter pylori-related gastroenterology studies sub-topic

This page shows what the Helicobacter pylori-related gastroenterology studies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
46 open questions have been extracted from the limitations and future-work passages of 497 Helicobacter pylori-related gastroenterology studies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.